Stock fact sheet · data as of
Aptevo Therapeutics Inc. (APVO): fair value, margin of safety and Wheel Score
Healthcare · Biotechnology · United States · Speculative / Distressed
Is APVO undervalued?
Aptevo Therapeutics Inc. (APVO) closed at 1.70 on 16 Oct 2026. The GLS average fair value - the simple average of the 1 valuation models that produced a positive number - is 5,120.14, which puts the price 100% below it. 1 of the 1 models value the shares above the current price. A gap this wide is rare in our universe of ~7,400 US stocks and is exactly what the Value part of the Wheel Score rewards; it is also where the question "why is it this cheap?" matters most.
Only 1 of the nine models produced a value (DCF); the others need a dividend, positive free cash flow or positive book value the company does not have yet, so the average rests on a narrow base.
The nightly engine files APVO under Speculative / Distressed - negative earnings or a Piotroski score of 3 or less - which caps its Wheel Score at 45 and keeps it out of the Sunday Scan.
Nine valuation models for APVO
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | 5,120.14 | +301085% | Present value of the projected free cash flows, discounted at the cost of capital |
| Graham Number | - | - | The most a defensive investor pays for the earnings and book value per share; no value tonight |
| Graham Growth | - | - | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields; no value tonight |
| Lynch | - | - | EPS × the earnings growth rate (PEG of 1), growth capped at 25%; no value tonight |
| GLS Growth | - | - | EPS compounded ten years at the blended growth rate, discounted back at 15% a year; no value tonight |
| 10 Cap | - | - | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%; no value tonight |
| Payback Time | - | - | Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | - | - | Earnings power value: current EPS capitalised at 9% with no growth; no value tonight |
| Zombie (liquidation) | 6.07 | +257% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 0.0000 | -100% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Financial health is weak: APVO passes 1 of the nine Piotroski tests. Our screens drop the stock at the health rule; a low score is often the reason a stock looks cheap on the valuation models. The GLS Moat score is low at 1.1 out of 10, which says the ten-year record of revenue, earnings, margins and returns on capital has been inconsistent - growth and shocks rather than steady compounding.
Returns on capital are thin or negative - ROIC -118.0%, ROE -149.4%, ROA -95.5% - with debt at 0.27 times equity and negative free cash flow.
Aptevo Therapeutics Inc. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain. Revenue comes mainly from Product 100% (fiscal year FY2019).
Institutional ownership scores 1/10, insider activity 10/10 and Congressional trading 5/10 on the GLS smart-money scales.
| Piotroski F-score | 1 / 9 | ROIC | -118.0% |
|---|---|---|---|
| GLS Moat | 1.1 / 10 | ROE | -149.4% |
| Debt / equity | 0.27 | ROA | -95.5% |
| Free-cash-flow yield | -681.7% | Payout ratio | 0% |
| Institutions | 1 / 10 | Insiders · Congress | 10 · 5 / 10 |
Wheel Score 33: No options
APVO has no listed options in the nightly snapshot, so there is nothing to sell and the stock cannot be wheeled however good the business; the Wheel Score is capped at 39 and shown as "No options" (33 here). The valuation and quality numbers still apply to owning the shares outright.
Volume runs at 11k shares a day on a market cap of $4M, with a beta of 1.68 - a high beta, so the stock tends to move more than the market and a strike can be gapped through; the Stability part of the Wheel Score gives that 4 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 25 / 25 | 100% margin of safety | |
| Health | 2 / 20 | Piotroski 1/9 | |
| Moat | 2 / 15 | moat 1.1/10 | |
| Premium | 0 / 20 | no option data | |
| Stability | 4 / 20 | 11k shares/day, $4M cap, beta 1.68 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
The next earnings report is due on 5 Nov 2026, 20 days away; a 30-45-day put sold today would expire after it, which is worth weighing against the premium.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Biotechnology
The 12 companies below are the closest to Aptevo Therapeutics Inc. by market cap within the Biotechnology industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| KALA KALA BIO, Inc. | 0.1922 | 40.66 | +100% | 39No options | $4M |
| ADXN Addex Therapeutics Ltd | 3.02 | 1.39 | -118% | 11No options | $4M |
| PMCB PharmaCyte Biotech, Inc. | 0.3485 | 2.22 | +84% | 38Weak | $4M |
| LNAI Lunai Bioworks Inc. | 0.8255 | 108.83 | +99% | 38Weak | $4M |
| ENLV Enlivex Therapeutics Ltd. | 0.2242 | 6,833.34 | +100% | 45Weak | $4M |
| DRMA Dermata Therapeutics, Inc. | 0.9100 | 7.66 | +88% | 39No options | $4M |
| ERNA Ernexa Therapeutics Inc. | 2.17 | 1.87 | -16% | 14No options | $4M |
| CVKD Cadrenal Therapeutics, Inc. Common Stock | 0.9700 | 1.73 | +44% | 36No options | $3M |
| EVGN Evogene Ltd. | 0.3999 | - | - | 24No options | $3M |
| CALC CalciMedica, Inc. | 1.08 | 0.0003 | -422318% | 13No options | $3M |
| JUNS Jupiter Neurosciences, Inc. | 3.14 | - | - | 26No options | $4M |
| CMND Clearmind Medicine Inc. | 6.42 | 7.99 | +20% | 31No options | $3M |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about APVO
Is APVO undervalued right now?
By the GLS models, yes: at 1.70 the stock is 100% below the average fair value of 5,120.14 (data as of 16 Oct 2026). Whether the discount is deserved is the question to research next.
What is the Wheel Score of APVO and what does it mean?
APVO has no listed options in our nightly snapshot, so it cannot be wheeled; its Wheel Score is capped at 39 and shown as "No options".
What is the GLS fair value for APVO?
5,120.14 per share as of 16 Oct 2026 - the simple average of the 1 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does Aptevo Therapeutics Inc. report earnings next?
The next earnings report is due on 5 Nov 2026, 20 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.
Does APVO have listed options, and how liquid are they?
No. The nightly options snapshot found no listed contracts on APVO, so the wheel strategy cannot be run on it and the Wheel Score is capped at 39.